ACTRN12616000411448Completed未知
Open, non-deceptive placebo administration to improve the re-epithelialisation rate of 4mm punch biopsy wounds in healthy participants
niversity of Auckland Masters Programme Funding0 sites68 target enrollmentStarted: March 31, 2016Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 68
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •Healthy participants who are able to understand and write in English.
Exclusion Criteria
- •Participants will be excluded if they smoke, have medical conditions that would affect wound healing (e.g. eczema, psoriasis, anemia, diabetes, etc.), regular use of other treatments affecting wound healing (e.g. anticoagulants, non-steroidal anti-inflammatories), or any surgery or tattoos within the last 30 days.
Investigators
Similar Trials
Completed
Not Applicable
Are pills enough? The influence of information on open-label placebo effects in healthy volunteersegative emotional statePositive mental wellbeingPhysical symptomsSleep qualityACTRN12617001092381Dr Kate Faasse90
Completed
Not Applicable
Influence of rituals on open-label placebo effect in healthy volunteersegative emotional statesPoor sleep qualityLow perceived well-beingPerceived fatigueNegative emotional statesAlternative and Complementary Medicine - Other alternative and complementary medicineMental Health - Studies of normal psychology, cognitive function and behaviourACTRN12620000305921Dr Kate Faasse101
Not yet recruiting
Unknown
Trial to determine the safety, efficacy and ease of use of Transdermal Application of Multi Nutrient LotioCTRI/2024/07/070555Murali Krishna Pharma Pvt Ltd
Recruiting
Phase 4
To evaluate the effect of Proxyvon capsules (combination of propoxyphene napsylate and paracetamol)on ECG of healthy human volunteers as compared to placebo.CTRI/2011/11/002143Wockhardt Limited12
Active, not recruiting
Phase 1
8 week study in asthmatic patients to look at the safety and effect of GSK2245035 on their asthmatic response after allergen exposure.EUCTR2015-005645-31-GBGlaxoSmithKline Research & Development Ltd36